Beta blockers and left ventricular hypertrophy in hypertension

Bruno Trimarco, Nicola De Luca, Alberto Cuocolo, Bruno Ricciardelli, Giovanni Rosiello, Giuseppe Lembo, Massimo Volpe

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

It is now generally accepted that hypertension-induced left ventricular hypertrophy (LVH) represents a phenomenon of multifactorial origin. Antihypertensive therapy with beta-blocking drugs influences most of the factors involved in the control of left ventricular mass. Therefore, although initial animal experiments yielded conflicting results, it is not surprising that a great deal of evidence has been accumulated in clinical studies showing that succesful long-term antihypertensive treatment with beta blockers induces regression of LVH in hypertensive subjects. Differences in molecular structure among various beta-blocking agents do not seem to influence this property. On the contrary, the question of whether reversal of LVH represents a beneficial or harmful byproduct of antihypertensive treatment with beta blockers is still unanswered. Animal and clinical studies suggest that left ventricular systolic function is unchanged or even improved after regression of LVH, whereas the ability of the heart to withstand recurrence of hypertension is slightly reduced. Furthermore, development of LVH in hypertensive subjects is associated with abnormalities in diastolic function which are not reduced by reversal of LVH induced by antihypertensive treatment with beta blockers.

Original languageEnglish
Pages (from-to)975-983
Number of pages9
JournalAmerican Heart Journal
Volume114
Issue number4 PART 2
DOIs
Publication statusPublished - 1987

Fingerprint

Left Ventricular Hypertrophy
Hypertension
Antihypertensive Agents
Molecular Structure
Left Ventricular Function
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Trimarco, B., De Luca, N., Cuocolo, A., Ricciardelli, B., Rosiello, G., Lembo, G., & Volpe, M. (1987). Beta blockers and left ventricular hypertrophy in hypertension. American Heart Journal, 114(4 PART 2), 975-983. https://doi.org/10.1016/0002-8703(87)90596-5

Beta blockers and left ventricular hypertrophy in hypertension. / Trimarco, Bruno; De Luca, Nicola; Cuocolo, Alberto; Ricciardelli, Bruno; Rosiello, Giovanni; Lembo, Giuseppe; Volpe, Massimo.

In: American Heart Journal, Vol. 114, No. 4 PART 2, 1987, p. 975-983.

Research output: Contribution to journalArticle

Trimarco, B, De Luca, N, Cuocolo, A, Ricciardelli, B, Rosiello, G, Lembo, G & Volpe, M 1987, 'Beta blockers and left ventricular hypertrophy in hypertension', American Heart Journal, vol. 114, no. 4 PART 2, pp. 975-983. https://doi.org/10.1016/0002-8703(87)90596-5
Trimarco B, De Luca N, Cuocolo A, Ricciardelli B, Rosiello G, Lembo G et al. Beta blockers and left ventricular hypertrophy in hypertension. American Heart Journal. 1987;114(4 PART 2):975-983. https://doi.org/10.1016/0002-8703(87)90596-5
Trimarco, Bruno ; De Luca, Nicola ; Cuocolo, Alberto ; Ricciardelli, Bruno ; Rosiello, Giovanni ; Lembo, Giuseppe ; Volpe, Massimo. / Beta blockers and left ventricular hypertrophy in hypertension. In: American Heart Journal. 1987 ; Vol. 114, No. 4 PART 2. pp. 975-983.
@article{9aea16d7ba3441eea388b8c9cde3323c,
title = "Beta blockers and left ventricular hypertrophy in hypertension",
abstract = "It is now generally accepted that hypertension-induced left ventricular hypertrophy (LVH) represents a phenomenon of multifactorial origin. Antihypertensive therapy with beta-blocking drugs influences most of the factors involved in the control of left ventricular mass. Therefore, although initial animal experiments yielded conflicting results, it is not surprising that a great deal of evidence has been accumulated in clinical studies showing that succesful long-term antihypertensive treatment with beta blockers induces regression of LVH in hypertensive subjects. Differences in molecular structure among various beta-blocking agents do not seem to influence this property. On the contrary, the question of whether reversal of LVH represents a beneficial or harmful byproduct of antihypertensive treatment with beta blockers is still unanswered. Animal and clinical studies suggest that left ventricular systolic function is unchanged or even improved after regression of LVH, whereas the ability of the heart to withstand recurrence of hypertension is slightly reduced. Furthermore, development of LVH in hypertensive subjects is associated with abnormalities in diastolic function which are not reduced by reversal of LVH induced by antihypertensive treatment with beta blockers.",
author = "Bruno Trimarco and {De Luca}, Nicola and Alberto Cuocolo and Bruno Ricciardelli and Giovanni Rosiello and Giuseppe Lembo and Massimo Volpe",
year = "1987",
doi = "10.1016/0002-8703(87)90596-5",
language = "English",
volume = "114",
pages = "975--983",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4 PART 2",

}

TY - JOUR

T1 - Beta blockers and left ventricular hypertrophy in hypertension

AU - Trimarco, Bruno

AU - De Luca, Nicola

AU - Cuocolo, Alberto

AU - Ricciardelli, Bruno

AU - Rosiello, Giovanni

AU - Lembo, Giuseppe

AU - Volpe, Massimo

PY - 1987

Y1 - 1987

N2 - It is now generally accepted that hypertension-induced left ventricular hypertrophy (LVH) represents a phenomenon of multifactorial origin. Antihypertensive therapy with beta-blocking drugs influences most of the factors involved in the control of left ventricular mass. Therefore, although initial animal experiments yielded conflicting results, it is not surprising that a great deal of evidence has been accumulated in clinical studies showing that succesful long-term antihypertensive treatment with beta blockers induces regression of LVH in hypertensive subjects. Differences in molecular structure among various beta-blocking agents do not seem to influence this property. On the contrary, the question of whether reversal of LVH represents a beneficial or harmful byproduct of antihypertensive treatment with beta blockers is still unanswered. Animal and clinical studies suggest that left ventricular systolic function is unchanged or even improved after regression of LVH, whereas the ability of the heart to withstand recurrence of hypertension is slightly reduced. Furthermore, development of LVH in hypertensive subjects is associated with abnormalities in diastolic function which are not reduced by reversal of LVH induced by antihypertensive treatment with beta blockers.

AB - It is now generally accepted that hypertension-induced left ventricular hypertrophy (LVH) represents a phenomenon of multifactorial origin. Antihypertensive therapy with beta-blocking drugs influences most of the factors involved in the control of left ventricular mass. Therefore, although initial animal experiments yielded conflicting results, it is not surprising that a great deal of evidence has been accumulated in clinical studies showing that succesful long-term antihypertensive treatment with beta blockers induces regression of LVH in hypertensive subjects. Differences in molecular structure among various beta-blocking agents do not seem to influence this property. On the contrary, the question of whether reversal of LVH represents a beneficial or harmful byproduct of antihypertensive treatment with beta blockers is still unanswered. Animal and clinical studies suggest that left ventricular systolic function is unchanged or even improved after regression of LVH, whereas the ability of the heart to withstand recurrence of hypertension is slightly reduced. Furthermore, development of LVH in hypertensive subjects is associated with abnormalities in diastolic function which are not reduced by reversal of LVH induced by antihypertensive treatment with beta blockers.

UR - http://www.scopus.com/inward/record.url?scp=0023201601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023201601&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(87)90596-5

DO - 10.1016/0002-8703(87)90596-5

M3 - Article

VL - 114

SP - 975

EP - 983

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4 PART 2

ER -